Abstract

Background: Hybrid coronary revascularization (HCR) represents a minimally invasive revascularization strategy in which the durability of the internal mammary artery to left anterior descending combined with percutaneous coronary intervention with drug eluting stents (DES) to treat remaining lesions in different coronary arteries.

Objective: To compare the complication like bleeding, nephropathy and hospital stay MACCE defined as death, stroke, myocardial infarction (MI), stroke, and repeat revascularization in hospital and one year follow up.

Methods: It was correctional study done UAE in 2018-2019 patient with multi vessel disease who consented with insurance approval were included and decision for which patient went HCR or CABG arm by heart team, patient underwent HCR we used stage manner first LIMA – LAD followed by multi vessel PCI after 24 hrs. And patient were discharged on day 5 of admission

Results: 15 patients underwent hybrid revascularization bleeding rate was high with OR OF 1.0 with 95% C.I of 0.8-1.3 with p value of 0.03, risk of Nephropathy was higher in HCR group with odd ration 1.2 (0.6-1.5) with p value of 0.04 the mean length was 5 vs 7 Days One stroke in CABG group and MACE was HCR with ODD ratio of 1.2 (95% CI 0.8-1.5 with p value of 0.04 observed till one year no in hospital death one year follow up. Three patients died of MACE in CABG and one patient in HCR group.

Keywords: Coronary Arteries Bypass Surgery, Hybrid Revascularization, Percutaneous Coronary Intervention Coronary Artery Disease, Left Internal Mammary Artery, Drug Eluting Stents

Introduction

Hybrid coronary revascularization is a treatment strategy for coronary artery disease (CAD), which offers an alternative to either traditional coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) alone. With the goal being to reduce the risk of the procedure and maximize the benefit, hybrid therapy capitalizes on the strengths of each approach. Since first being described by Angelina and colleagues in 1996, Hybrid coronary revascularization (HCR) procedures introduced in 2011 by the American Heart Association/American College of Cardiology Foundation updated guidelines for coronary artery bypass grafting (CABG) surgery [1,2]. The LIMA-LAD graft may be responsible for the majority of the benefit of CABG surgery. Whether non-LAD vessels are treated with SVGs or PCI may be less important. This is the premise on which the modern era of hybrid coronary revascularization is based. Advances in both surgical and catheter-based techniques have made hybrid therapy a more attractive option for the treatment of multi-vessel CAD. Using one of several minimally invasive techniques, the left anterior descending coronary artery is grafted with the left internal mammary (LIMA), and percutaneous intervention is applied to single or two vessel coronary arteries. In this approach, the well-established survival benefit of the LIMA graft is capitalized upon and, being done with minimally invasive techniques, the increased morbidity of a full sternotomy is avoided. Additionally, the use of the LIMA graft confers benefit related to the relief of angina and long-term patency [3]. Newer generation drug eluting stents have continued to improve long-term patency following PCI, to rates similar to or even surpassing that of saphenous vein grafts [4,5]. Smaller series continue to be published some study [6-8]. The advantage elderly patient specially women high-risk patients (recent myocardial infarction, prior stroke, frailty, end-stage renal disease on dialysis) in whom a less invasive approach may reduce the operative time and ischemic time [9-11].
**Methodology**

Total 15 patients were enrolled in a study where their baseline characteristics were collected from electronic medical records, as shown in Table 1. Patients who underwent HCR with surgical LIMA grafting to the LAD combined with PCI to non-LAD vessels (hybrid group). The selection of HCR or CABG for revascularization was at the discretion of the clinical site cardiologist and surgeon. Comparative effectiveness trial of HCR and CABG were used in this observational study to compare clinical outcomes with Hybrid vs CABG.

Table 1: Baseline Clinical Features of Patients

<table>
<thead>
<tr>
<th>Comorbid</th>
<th>HRS Group n 7</th>
<th>CABG n 8</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>70 years</td>
<td>56 years</td>
<td>0.04</td>
</tr>
<tr>
<td>Race</td>
<td>Bangladesh</td>
<td>Bangladesh</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>Pakistan</td>
<td>Pakistan</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>Indian</td>
<td>Indian</td>
<td>ns</td>
</tr>
<tr>
<td></td>
<td>UAE residents</td>
<td>UAE</td>
<td>0.05</td>
</tr>
<tr>
<td>Female</td>
<td>9</td>
<td>6</td>
<td>0.05</td>
</tr>
<tr>
<td>HTN (greater than 150/100)</td>
<td>20%</td>
<td>30%</td>
<td>0.2</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Mean HBAIC 6.7%</td>
<td>7.7%</td>
<td>0.05</td>
</tr>
<tr>
<td>Mean BMI kg/m²</td>
<td>29kg/m²</td>
<td>26kg/m²</td>
<td>0.03</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>Mean LDL 140 mg/dl%</td>
<td>130mg/dl</td>
<td>0.6</td>
</tr>
<tr>
<td>Renal failure GFR</td>
<td>1 patients</td>
<td>3 patients</td>
<td>0.05</td>
</tr>
<tr>
<td>Mean EF</td>
<td>38%</td>
<td>45%</td>
<td>0.04</td>
</tr>
<tr>
<td>Prior stroke</td>
<td>5</td>
<td>2</td>
<td>0.05</td>
</tr>
<tr>
<td>Prior MI</td>
<td>9</td>
<td>4</td>
<td>0.055</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>1</td>
<td>8</td>
<td>0.05</td>
</tr>
</tbody>
</table>

**Inclusion Criteria**
- Elderly patient specially women
- High-risk patients (recent myocardial infarction, prior stroke, frailty, end-stage renal disease on dialysis
- Nephropathy A GFR of 50 ml/min.
- Patients who have left vein disease with multivessel will excluded for HRS
- Patient with low heart function EF as measured by echo <35%

**Exclusion Criteria**
- Patient with concomitant left main disease with other coronary artery disease
- Patient with three vessel disease with long diffuse disease
- Patient have valvular heart disease with multi vessel CAD
- GFR below 30ml/min.

**Statistical Analysis**

Data was entered in SPSS version 24 base line characteristics were compared by using independent T test and chis-square test with p value less than 0.5 was considered significant and for outcome variable multiple variate logistic regression analysis by calculating ODD ration with 95% confidence interval with p value less the 0.05 was consider significant.

**Intervention**

HCR was defined as a planned surgical revascularization of the LAD combined with percutaneous revascularization of at least one non-LAD target and stenting of other lesions by PCI with DES was done after 24 hrs. Conventional CABG was performed by all the surgical venous and arterial conduit.

**Outcome Measures**

The primary outcome was the incidence of MACC bleeding, nephropathy hospital stay defined as death, stroke, myocardial infarction (MI), or repeat revascularization at 12 months following the initial procedure described in Table 2.

Table 2: In Hospital Outcomes Measurement in Two Groups

<table>
<thead>
<tr>
<th>Outcome</th>
<th>HRS</th>
<th>CABG</th>
<th>ODD ratio</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleeding</td>
<td>5</td>
<td>3</td>
<td>1.2 (95% CI 0.9-1.5)</td>
<td>0.4</td>
</tr>
<tr>
<td>Stroke</td>
<td>no</td>
<td>1</td>
<td>2 (95% CI 1-3)</td>
<td>0.6</td>
</tr>
<tr>
<td>Mean hospital stay</td>
<td>5 days</td>
<td>12 days</td>
<td>OR 1.1 (95% CI 1.09-1.4)</td>
<td>0.01</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>3</td>
<td>1</td>
<td>1 (95% CI 0.9-1.5)</td>
<td>0.03</td>
</tr>
<tr>
<td>RE MI</td>
<td>3</td>
<td>1</td>
<td>1 (95% CI 0.9-1.5)</td>
<td>0.05</td>
</tr>
<tr>
<td>Repeat revascularization</td>
<td>3</td>
<td>i</td>
<td>1.2 (95% CI 0.8-1.5)</td>
<td>0.04</td>
</tr>
<tr>
<td>Death</td>
<td>o</td>
<td>o</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
Results
In HCR more elderly more patient which have high risk features like prior stroke MI in CABG group more patient with diffuse CAD more obese and more patient having peripheral vascular disease no gender difference in both groups and interesting 14 patients were Asian Expect Racial difference in CAD needs to be further trials is the contribution of genetics play a role in high CAD in UAE.

Selection of Patient in Both Groups
Heart team interventional cardiologist 2 and 2 cardiac surgeon and Cath lab nurse did selection.

HCR Group
• NSTEMI n 3 patients AWMI 2 patients
• Coronary anatomy coronary total LAD obstruction (CTO) discrete lesion LCX and RCA and EF 35% first underwent lima to LAD mini key hole surgery remain if remained stable after 24 hrs., PCI of LCX and RCA was done with DES
  • Mean EF 38%
  • No procedure complication
  • Contrast used was 70 cc patient
  • Total hospital stay was 4 days
  • Use of GP 11b/11a inhibitors in 3 patients
  • Bleeding complication at side of PCI 3 patients

one case of HCR was described this patient presented with acute AWMI coronary anatomy showed osteal LAD with short left main underwent LIMA to LAD and long lesion with 99% RCA EF 40% procedure was uncomplicated hospital stay was 8 days Pic of HRS (123).

Figure 1: Pre and post procedure with LIMA CTO LAD
CABG Group

- 3 patients with NSTEMI 5 with unstable angina
- Coronary anatomy 3 patients had LM disease 3 had diffuse three vessel disease
- Mean EF >40
- Bleeding complications in three patients because of reopening
- Use of GP11B/111a and dual ant plates in 4
- No procedure complication
- Mean Hospital stay was 12 days

In Hospital HCR group has more bleeding lesser mean hospital stay but more Repeat revascularization because of high-risk profile of patient acute AWMI low EF use of GPII/IIIa inhibitors. Better patient satisfaction and low cost In CABG one patient required reopening because of bleeding that lengthen mean stay one stroke no inpatient mortality one patient need repeat revascularization. One-year follow up 3 patients in CABG died of MACE in HCR patient 2 developed nephropathy but not requiring dialysis MACE in two patient required repeat revascularization one patient died of MI.

Discussion

Types of Hybrid Revascularization -stage hybrid: CABG/PCI performed in a hybrid room and in one setting, staged by minutes or days the appeal of the latter is multifold: improved logistics, lower cost, and better patient satisfaction [12,13]. As in our study, PCI before CABG allows aggressive stunting because if a complication arises or PCI is unsuccessful, CABG can be performed later. Main disadvantage: Performing PCI in an unprotected environment without the benefit of a LIMA-LAD graft and later performing CABG under aggressive antiplatelet agents. PCI after CABG Avoids ant platelet-related bleeding complications CABG has advantage-protected environment with a LIMA-LAD graft LIMA graft patency can be verified at the time of PCI. Disadvantage: In the event of PCI complication/ failure, however, a second, higher-risk operation needs to be performed. The latter should be rare, however, as emergent CABG after PCI has a low incidence (<1%) Halkos, et al recently published Study what may be the largest series to date, in which 147 patients who underwent hybrid revascularization between 2003 and 2010 were compared in a 4:1 ratio to patients undergoing multi-vessel off-pump CABG [14]. According to ClinicalTrials.gov, the Hybrid Revascularization Observational Study, funded by the National Heart Lung and Blood Institute, has recently been completed [15]. The largest observational study to date,14 with planned enrollment of over 6000 patients, this study was intended to inform the design of a pivotal comparative effectiveness trial and more optimally identify the population for whom hybrid therapy may be the better option. Primary outcomes are a composite of death, stroke, MI, or repeat revascularization with follow up over 18 to 21 months. To date, no data was published.
from this study. As noted previously, the numerous studies that have been published to date vary in the surgical and interventional followed by PCI techniques, as well as patient selection, anti-platelet strategies and one-stop vs staged approaches as in our study use of gpIIb/IIIa inhibitors and antiplatelet were not started as we do LIMA to LAD with PCI, the location of the lesion in the proximal LAD has been identified as an independent risk factor for in-stent rest enosis with rates between 19% and 44% [16-18]. As occurred in our study with osteal LCX requiring Repeat PCI the LIMA–LAD graft has excellent patency rates, which correlates with increased event-free survival. 5-year patency rate ranges between 92% and 99% and at 10 years between 95% and 98%.

With PCI, the location of the lesion in the proximal LAD has been identified as an independent risk factor for in-stent rest enosis with rates between 19% and 44%. The LIMA–LAD graft has excellent patency rates, which correlates with increased event-free survival. 5-year patency rate ranges between 92% and 99% and at 10 years between 95% and 98%. In control trial 104 patients with average 18 months follow-up Hybrid significantly reduced in-hospital time and transfusion rate Lower MACCE rate 99% vs. 90.4% than Off-pump after 18 months follow-up as described by PR Moreno 2020 JACC Review showed less MACE as our finding. HRS technique has advantages in elderly similar fining described in journal of Geriatric [19-23].

**Limitation of our study**

This was observational study with only six patients because its novel technique and lot of cost we need large randomized trial for efficacy hybrid revascularization.

**Strength of the study**

It introduced the patient’s alternative option for patients, which are high risk for surgery, are benefited from HRS and more patient satisfaction less MACE and shorter stay.

**List of Abbreviations**

- **CAD:** Coronary Artery Disease
- **PCI:** Percutaneous Coronary Intervention
- **HRS:** Hybrid Revascularization
- **LIMA:** Left Internal Mammary Artery
- **LCX:** Left Circumflex Artery
- **RCA:** Right Coronary Artery
- **LAD:** Left Anterior Descending Artery
- **CTO:** Chronic Total Occlusion
- **DES:** Drug Eluting Stents
- **GFR:** Glomerular Filtration rate ml/min

**Conclusion**

In this study, we found hybrid revascularization has more benefits less MACE, patient satisfaction and decrease stay in hospital and one-year follow up compared to CABG patients. We need larger scale studies, training of heart team for hybrid revascularization and more centers should be open for hybrid revascularization, population should be benefited with because CABG refusal is high so death from coronary disease is also is no one cause of death in patients with multivessel disease with low heart function will be reduced the one factor which need attention as this study was done in UAE where insurance covered the procedure but in Pakistan this issue needs to be discussed health policy maker.

**References**


